Related references
Note: Only part of the references are listed.The management of post-transplantation recurrence of hepatocellular carcinoma
Luckshi Rajendran et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2022)
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Keisuke Koroki et al.
LIVER CANCER (2021)
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
Tatsuya Yamashita et al.
JOURNAL OF GASTROENTEROLOGY (2020)
Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma
Lorenza Rimassa et al.
LIVER INTERNATIONAL (2020)
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
Jaekyung Cheon et al.
LIVER CANCER (2020)
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
Sojung Han et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Cheol-Hyung Lee et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Robin Kate Kelley et al.
ESMO OPEN (2020)
Long-term prognosis and management of hepatocellular carcinoma after curative treatment
Naoshi Nishida
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
Tetsu Tomonari et al.
JGH OPEN (2020)
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018)
A. Vogel et al.
ANNALS OF ONCOLOGY (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Thomas Yau et al.
JOURNAL OF HEPATOLOGY (2019)
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma
Changhoon Yoo et al.
INVESTIGATIONAL NEW DRUGS (2019)
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
Nicola Personeni et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2019)
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Joong-Won Park et al.
KOREAN JOURNAL OF RADIOLOGY (2019)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesus Prieto et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
Feng Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
